1. Home
  2. GBIO vs CRVO Comparison

GBIO vs CRVO Comparison

Compare GBIO & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • CRVO
  • Stock Information
  • Founded
  • GBIO 2016
  • CRVO 2001
  • Country
  • GBIO United States
  • CRVO United States
  • Employees
  • GBIO N/A
  • CRVO N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • CRVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBIO Health Care
  • CRVO Health Care
  • Exchange
  • GBIO Nasdaq
  • CRVO Nasdaq
  • Market Cap
  • GBIO 145.5M
  • CRVO 160.4M
  • IPO Year
  • GBIO 2020
  • CRVO N/A
  • Fundamental
  • Price
  • GBIO $2.16
  • CRVO $16.30
  • Analyst Decision
  • GBIO Buy
  • CRVO Strong Buy
  • Analyst Count
  • GBIO 4
  • CRVO 4
  • Target Price
  • GBIO $7.50
  • CRVO $58.25
  • AVG Volume (30 Days)
  • GBIO 66.5K
  • CRVO 68.7K
  • Earning Date
  • GBIO 08-07-2024
  • CRVO 08-09-2024
  • Dividend Yield
  • GBIO N/A
  • CRVO N/A
  • EPS Growth
  • GBIO N/A
  • CRVO N/A
  • EPS
  • GBIO N/A
  • CRVO N/A
  • Revenue
  • GBIO $13,174,000.00
  • CRVO $9,653,281.00
  • Revenue This Year
  • GBIO $99.36
  • CRVO $47.04
  • Revenue Next Year
  • GBIO N/A
  • CRVO N/A
  • P/E Ratio
  • GBIO N/A
  • CRVO N/A
  • Revenue Growth
  • GBIO 1397.05
  • CRVO 585.67
  • 52 Week Low
  • GBIO $0.86
  • CRVO $4.28
  • 52 Week High
  • GBIO $4.83
  • CRVO $26.38
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 39.06
  • CRVO 44.35
  • Support Level
  • GBIO $2.16
  • CRVO $14.00
  • Resistance Level
  • GBIO $2.49
  • CRVO $18.63
  • Average True Range (ATR)
  • GBIO 0.21
  • CRVO 1.71
  • MACD
  • GBIO -0.03
  • CRVO -0.25
  • Stochastic Oscillator
  • GBIO 3.85
  • CRVO 3.02

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About CRVO CervoMed Inc.

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Share on Social Networks: